
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
Nearly all of us use and depend on computers for running and operatingour medical offices. I doubt that many of us could successfully operateour practices without this evolving technology, which adds not only to improvementin the medical care we offer our patients but to the efficiency of our practices.






